ACOR Acorda Therapeutics Inc.

+0.06  (+7%)
Previous Close 0.87
Open 0.92
Price To Book 0.14
Market Cap 44,637,231
Shares 47,997,023
Volume 759,827
Short Ratio
Av. Daily Volume 1,543,255
Stock charts supplied by TradingView

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 1 complete. Noted November 2017 that it will not advance into a Phase 2 study by the end of 2017, as previously expected. Evaluating next steps.
Noted November 15, 2017 seven cases of sepsis, five of which were fatal. Company noted November 20, 2017 that program will be discontinued.
Parkinson’s disease (PD)
Phase 3 data released November 21, 2016 - failed to show efficacy, development to be discontinued.
Post stroke deficits
FDA Approval announced December 22, 2018.
OFF episodes of Parkinson’s disease (PD)
Phase 2 interim data were slated for 3Q 2018 - no update given to date from company.
Primary Sclerosing Cholangitis